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Summary
Sudden unexpected death of an individual with epilepsy can pose a challenge to death 
investigators, as most deaths are unwitnessed, and the individual is commonly found dead in bed. 
Anatomic findings (eg, tongue/lip bite) are commonly absent and of varying specificity, thereby 
limiting the evidence to implicate epilepsy as a cause of or contributor to death. Thus it is likely 
that death certificates significantly underrepresent the true number of deaths in which epilepsy was 
a factor. To address this, members of the National Association of Medical Examiners, North 
American SUDEP Registry, Epilepsy Foundation SUDEP Institute, American Epilepsy Society, 
and the Centers for Disease Control and Prevention constituted an expert panel to generate 
evidence-based recommendations for the practice of death investigation and autopsy, toxicological 
analysis, interpretation of autopsy and toxicology findings, and death certification to improve the 
precision of death certificate data available for public health surveillance of epilepsy-related 
deaths. The recommendations provided in this paper are intended to assist medical examiners, 
coroners, and death investigators when a sudden unexpected death in a person with epilepsy is 
encountered.
Keywords
autopsy; death investigation; epilepsy; mortality; sudden unexpected death in epilepsy
1 INTRODUCTION
The investigation and certification of deaths in patients with seizures and epilepsy vary 
within and between medical examiners’ and coroners’ offices.1,2 This variation, together 
with varied terms and criteria to diagnose and classify seizures and epilepsies, and possible 
comorbid disease (eg, cardiovascular), challenges the determination of cause of death (COD) 
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in seizure- and epilepsy-related death, and likely underestimates the frequency of these 
deaths.
To help address these limitations, the National Association of Medical Examiners, North 
American SUDEP Registry, Epilepsy Foundation SUDEP Institute, American Epilepsy 
Society, and the Centers for Disease Control and Prevention (CDC), constituted an expert 
panel (pathologists/medical examiners [7], epileptologists [6], epidemiologists [3], 
cardiologist [1], and a health sciences librarian [1]) to establish recommendations for death 
investigation and certification of epilepsy-related deaths. The peer-reviewed literature was 
examined for deaths among individuals with seizures and epilepsy. The goal was to better 
inform of the public health burden of seizures and epilepsy-related death and improve 
surveillance by developing evidence-based recommendations for the practice and 
interpretation of death investigation, autopsy, toxicological analysis, and death certification. 
The panel formulated 7 questions to address best practices for effective identification of 
seizure- and epilepsy-related death (Table 1). These questions were arranged in the order 
that typically arises during death investigation. The recommendations were reviewed by 
each society for comments and eventual endorsement. Respective organizations at CDC also 
provided review and comment.
2 BACKGROUND
A seizure is a sudden behavioral change resulting from excessive synchronous electrical 
activity in the brain. Seizures may be provoked (also known as acute symptomatic; eg, fever 
in a young child, drug intoxication or withdrawal, electrolyte imbalance) or unprovoked, 
resulting from a genetic, developmental, acquired (eg, trauma, tumor, stroke), or unknown 
cause. Epilepsy is diagnosed when a person has 2 or more unprovoked seizures or has a 
single unprovoked seizure with an enduring tendency for additional seizures.3 “Seizure 
disorders” are aggregated with “seizures” in the National Vital Statistics System. However, 
seizure disorder can refer to individuals without epilepsy (eg, 2 provoked seizures). Because 
of these potential confounds, we recommend the term epilepsy over seizure disorder when 
clinically defined.
Epilepsy affects 3.4 million Americans.4 Individuals with epilepsy have up to 11-fold higher 
mortality rates compared to matched controls.2 Natural causes of death are increased 15-
fold. Nonnatural causes are also increased (falls—8-fold; drowning—7.7-fold; drug 
poisoning—5.1-fold; suicide 3.5 to 5-fold).5 Psychiatric disorders occur in 75% of those 
with nonnatural causes. Among United States young adults with epilepsy and low 
socioeconomic status, deaths occur 17 years prematurely.6
The incidence of sudden death among young adults with epilepsy is 24- to 27-fold higher 
than in control populations.7,8 Sudden unexpected death in epilepsy (SUDEP) is a sudden, 
unexpected, witnessed or unwitnessed, non-traumatic and nondrowning death, occurring in 
benign circumstances, in an individual with epilepsy, with or without evidence for a seizure 
and excluding documented status epilepticus, in which postmortem examination does not 
reveal a cause of death (Definite SUDEP), without postmortem examination but without 
other potential cause of death (Probable SUDEP), or with a competing cause of death 
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(Possible SUDEP). The strongest risk factor for SUDEP is poor control of primary or 
secondary generalized tonic–clonic seizures (GTCS).9 Structural brain lesions, focal 
abnormalities on neurological examination, intellectual disability, alcohol abuse, and 
anxiolytic use are associated with increased SUDEP risk in some studies.9,10
A potential confound in SUDEP is sudden cardiac death (SCD). Among “SCDs” in epilepsy 
patients, 70% are unwitnessed; 34% of witnessed cases had seizure activity before “SCD.”11 
Because 90% of SUDEPs are unwitnessed, a most people with epilepsy whose deaths were 
classified as “SCD” may have died from epilepsy. Misclassification of an epilepsy-related 
death as SCD is supported by higher rates of bradyarrhythmias and asystole (typical of 
epilepsy) and lower rates of ventricular arrhythmias in epilepsy patients with “SCD” than in 
nonepilepsy patients. In addition,, moderate coronary artery disease can suggest a primary 
cardiac cause of death in a person with epilepsy (PWE) but cannot exclude an epilepsy-
related death.
3 METHODS
We conducted electronic literature searches using the databases Medline (Ovid), Medline In-
Process & other Non-indexed Citations (Ovid), Embase (Ovid), and PubMed.gov for articles 
published in English from 1970 to January 2016. Databases were searched using both 
subject headings and text keywords that describe epilepsy-related mortality and death 
investigation (the complete search strategy is in the Appendix). Academic Forensic 
Pathology was also searched with keywords related to epilepsy and seizure.
Pairs of authors reviewed all the references yielded from the literature search using a 2-step 
process. First, the authors reviewed the titles and abstracts of the articles yielded from the 
search and excluded all irrelevant articles. The full text of the remaining articles was then 
reviewed for potential inclusion based on relevance to at least one of the questions and the 
evidence quality.
4 RESULTS/DISCUSSION
4.1 Question 1: Within the bounds of state law, which deaths in people with epilepsy 
require assumption of jurisdiction, and performance of an autopsy?
Medical examiners and coroners (ME/C) have the expertise and responsibility to determine 
the cause and manner of death in cases of sudden unexpected death. These circumstances are 
commonly encountered in the deaths of epilepsy patients, leading to ME/C involvement in 
most of these death certifications.12 ME/C authority to assume jurisdiction or responsibility 
for these determinations is typically mandated by their respective state statutes. Beyond 
statute, the ME/C exercises their professional judgement on jurisdiction, taking into account 
the circumstances of the death and resources available in their jurisdiction.
The process of assuming jurisdiction begins when a death is reported to the local ME/C, 
which requires awareness by reporting agencies and medical personnel of established 
criteria of reportable deaths. This initial connection is critical to identify epilepsy-related 
deaths; ME/C staff must consider the potential role of epilepsy in such instances. Once 
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jurisdiction is assumed, an investigation ensues to acquire the information necessary for 
cause and manner of death determinations, which in turn, are documented in the death 
certificate. In a retrospective study of SUDEP death certification in Britain, inconsistencies 
were identified in the depth of investigations. Causes of deaths varied, “with epilepsy stated 
as the primary cause of death in less than half the sample.”13
Autopsy may provide otherwise unavailable information necessary for death certification. 
The importance of complete autopsy is highlighted by a multidisciplinary team study of 335 
consecutive presumed sudden cardiac deaths over a 2-year period. This study, which 
included complete autopsy and investigative data, concluded that 18 cases (5.4%) were 
actually neurologic deaths, including 6 SUDEP.14 A national survey was done to assess the 
depth and frequency of forensic autopsies in SUDEP. Generally, the autopsies were done in a 
consistent manner, but the surveys identified a trend of nonurban offices performing fewer 
autopsies.15 If the circumstances surrounding a seizure death clearly indicate a natural event, 
jurisdiction may be declined by the ME/C, and an autopsy is not performed unless the 
family consents to a hospital autopsy or private autopsy. However, because this population 
tends to be younger and their deaths are frequently unwitnessed, autopsy is often required 
due to absence of an obvious natural cause.
Epilepsy death investigation is strongly dependent on history and scene findings, yet an 
autopsy is essential in excluding other causes of death, documenting comorbidities, 
obtaining toxicologic and histology samples, and providing neuropathologic correlation.
4.2 Question 2: What constitutes appropriate and necessary scene investigation, epilepsy 
screening, and follow-up?
The panel supports the practices recommended in the United States Department of Justice 
(USDOJ) National Institute of Justice (NIJ) Death Investigation Guidelines published by the 
USDOJ.16 When death occurs outside the hospital, the environment and position of the body 
should be detailed to help objectively interpret the circumstances. For example, 
understanding whether a PWE was found submerged in a bathtub full of water or prone on a 
bed with the external airways occluded by bedding material is crucial for eventual death 
certification. Knowing whether a death was witnessed or unwitnessed is also important. If 
witnessed, investigators should ask if the decedent had a seizure before becoming 
unresponsive and attempt to describe the initial behavioral changes or seizure movements. 
Documentation should include observations supportive of a tonic–clonic seizure event, such 
as disheveled bedding; biting of the tongue, lip, or cheek; or saliva/foam around the mouth. 
Medications and medication containers at the scene should be inventoried, especially 
antiepileptic drugs.
Investigators should ask family or other witnesses at the scene about the decedent’s medical 
history, striving for as specific of an epilepsy diagnosis as possible. At a minimum, the 
investigator should try to determine whether a decedent had convulsive or nonconvulsive 
seizures because this history may only be obtained with specific questions, and convulsive 
seizures significantly increase the risk of SUDEP (an example of questions to assist death 
investigators in gathering such information is provided in the Appendix). Primary care 
providers and neurologists should be contacted in follow-up, when known. If emergency 
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medical personnel responded to the scene, those records should be reviewed, and a copy of 
available electrocardiograph tracings/interpretations should be sought.
4.3 Question 3: When is it appropriate or necessary to perform toxicology and/or 
antiepileptic seizure medication testing?
In the absence of a specific anatomic cause of death following autopsy, when specimens are 
available, toxicology testing, including antiepileptic drug concentrations, should be 
performed. Results may reveal drug toxicity from illicit or prescribed substances as a 
potential cause of death. Documentation of postmortem antiepileptic drug concentrations 
can aid the investigation when death is potentially epilepsy-related. If the decedent was 
admitted to an emergency department or hospital before death, postmortem testing should be 
performed on the earliest blood specimen.
4.4 Question 4: What are the best samples to collect for laboratory testing and histologic 
analysis?
Blood, tissue, and other fluid samples should be retained as per the jurisdiction’s usual 
protocol for routine toxicology testing. Special consideration should be given for potential 
genetic studies, given the more than 100 genetic disorders associated with epilepsy, with 
new genes identified each year. Genetic channelopathies, most often sodium and potassium 
channel gene mutations, may contribute to SUDEP, since these genes are expressed in the 
brain and heart, and may lower seizure threshold and cause cardiac arrhythmias.17,18 Given 
the possible implications for surviving relatives, collection of proper samples is essential. An 
ethylenediaminetetraacetic acid (EDTA—purple top) tube of blood is the preferred specimen 
for genetic testing, but a blood spot card or frozen tissue (1 cubic centimeter of liver, spleen, 
or heart at −80°C) can also be used.19
Extended brain examination is recommended in potential epilepsy-related death cases, 
following brain fixation in formalin solution for a minimum of 2 weeks. Although 
examination by a neuropathologist is preferred, limitation of resources, objection to organ 
retention, or other factors will necessitate the autopsy pathologist’s discretion for such 
consultation. Previously published recommendations for microscopic analysis of the brain 
are outlined in Table 2. Patients with epilepsy may have cardiac pathology resulting from 
seizures as well as comorbid disorders (eg, hypertension, hyperlipidemia), with findings of 
irreversible changes characterized by myocyte hypertrophy and perivascular and interstitial 
fibrosis, and reversible change characterized by subendocardial myocyte vacuolization.20 
Others have recommended inclusion of 3 left ventricle and 1 right ventricle heart sections, 
lung, and any grossly abnormal organs for histologic examination, but individual practice 
varies.21
4.5 Question 5: How are scene findings, autopsy findings, toxicology, and histology 
interpreted?
In epilepsy-related deaths, the purposes of the scene investigation, autopsy, and ancillary 
tests are the following: (1) to determine that epilepsy has/has not caused or contributed to the 
death; (2) to identify the underlying etiology of epilepsy, if present; and (3) to assess 
comorbidities. Autopsy and ancillary test findings must be interpreted in the context of a 
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thorough death investigation to accurately determine the cause and manner of death. The 
utility and limitations of several anatomic findings frequently encountered in epilepsy-
related deaths are discussed.
4.5.1 Livor pattern/body position—The distribution of livor mortis may help in the 
context of positional asphyxia or smothering, by revealing pressure marks from objects 
against the chest, neck, nose, or mouth that may have restricted breathing. The extent to 
which such external factors contribute to death vary from case to case. Prone position is 
associated with SUDEP.23 The significance of finding the decedent’s face (nose/mouth) 
against a surface (often bedding) must be interpreted in the totality of autopsy and scene 
findings. Such a position is potentially threatening when the brain’s reflexive response to the 
environmental challenge is impaired, for example, during intoxication or during/after 
seizure. Without the seizure or postictal state, the environmental challenge would have been 
nonlethal. In some cases, livor pattern and scene reconstruction reveal evidence of an 
asphyxial component by compression of the chest or neck, with or without petechiae. 
Although historically considered an indicator of asphyxia and found in some SUDEPs,24,25 
petechiae occur in deaths resulting from diverse mechanisms and causes and therefore do 
not establish terminal asphyxia without corroborating findings and circumstances.
4.5.2 Tongue, lip, or inner cheek trauma—Contusion or laceration of the tongue, lip, 
or inner cheek supports, but is not diagnostic of, a seizure. Tongue trauma occurs in 17%–
50% of seizure-related deaths.24,26,27 Tongue trauma in other causes of death is uncommon; 
1 study found tongue/lip contusions in 37% of SUDEP cases but no controls.25 It is worth 
removing the tongue for examination. Trauma to the sides of the tongue or involving the 
buccal mucosa may be more helpful, since small contusions of the tongue tip may occur 
during intubation/attempted intubation.
4.5.3 Incontinence of urine—Although a helpful sign in evaluating living patients with 
epilepsy, urinary incontinence is so ubiquitous at death scenes that it cannot establish the 
occurrence of a terminal seizure.
4.5.4 Gastric contents in airway—Gastric contents are frequently found in the airways 
at autopsy, having been displaced there during compressions of the chest for resuscitation, 
during manipulation of the body after death, or by increased abdominal pressure during 
decomposition. The presence of gastric contents in the trachea and proximal bronchi should 
not be interpreted as mechanistically significant to the cause of death or as evidence of 
seizure activity and therefore does not exclude SUDEP.28 Abundant gastric contents in distal 
airways is more concerning for true aspiration if there was no mechanical ventilation or 
chest compressions. Occlusion of the upper airway by food is a significant finding and a 
choking event must be considered; such a death is not SUDEP but is epilepsy-related if the 
individual was eating when a seizure occurred.28
4.5.5 Pulmonary edema—Pulmonary edema is a nonspecific finding, commonly found 
at autopsy in deaths of various neurogenic or cardiogenic causes, including SUDEP. In 
animal models, neurogenic pulmonary edema in seizure deaths may result from a 
sympathetic surge with increased hydrostatic pressure in the left atrium, pulmonary artery, 
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and pulmonary microvasculature, leading to a capillary-alveolar membrane with increased 
permeability.29 Autopsy series of SUDEP show that pulmonary edema and congestion occur 
in 62%–100% of cases,20,27,30–32 but fail to demonstrate a statistically significant increase 
between SUDEP and controls.25,33 The absence of pulmonary edema does not exclude an 
epilepsy-related death.
4.5.6 Bronchopneumonia—Aspiration during seizure may lead to bronchopneumonia 
and result in a delayed, epilepsy-related death. Bronchopneumonia as a mechanism of death 
is 2.7- to 10.3-fold more common among people with epilepsy.2 Because delayed deaths 
would not be classified as SUDEP, it is useful to include the mechanism 
(bronchopneumonia) as well as the cause (epilepsy) on the death certificate for correct 
coding.
4.5.7 Neuropathologic findings—Neuropathologic examination can exclude competing 
causes of death, identify potentially epileptogenic lesions, and determine whether repeated 
seizures have caused brain injury (eg, hippocampal sclerosis or cerebellar atrophy). The 
brain should be examined after formalin fixation in seizure-related deaths when possible. 
Many lesions are easily identified (trauma, tumors, vascular malformations, abscesses, cysts, 
and so on), but some are difficult to identify, and microscopic findings can be subtle. Ideally, 
the brain should be examined by a neuropathologist. In 1 series, abnormalities were found in 
66% of formalin-fixed brains by formal neuropathologic examination versus 8.8% of brains 
examined in the fresh state.34 Histologic examination should be performed even when no 
macroscopic pathology is identified. However, absence of neuronal injury or identifiable 
pathology is consistent with the clinical diagnosis of epilepsy.
A common misconception is that the brain is normal anatomically in most SUDEP cases. 
Neuropathologic abnormalities in autopsy series of SUDEP and epilepsy-related deaths 
occur in 46%–71%.26,30,35 The SUDEP criterion that no anatomic cause of death be 
identified refers to competing (non–epilepsy-related) causes, not to the lack of an anatomic 
etiology for the epilepsy. Persons with epilepsy of any etiology may die suddenly and 
unexpectedly.
Seizure and epilepsy can result from diverse brain pathologies such as trauma, tumor, 
vascular malformation, cerebral infarct, abscess, parasitic cysts, Rasmussen encephalitis, 
other chronic encephalitis, and malformations of cortical development. Mesial temporal 
sclerosis refers to chronic changes in the hippocampus (hippocampal sclerosis), amygdala, 
and entorhinal cortex that are closely associated with temporal lobe epilepsy. Mesial 
temporal sclerosis/hippocampal sclerosis may be a complication or cause of epilepsy and 
does not need to be on the death certificate. The diverse neuropathologic findings in patients 
with epilepsy have been reviewed,36–38 and are beyond the scope of this article. When a 
neuropathologic lesion or disease is a probable cause of epilepsy, it should be listed as the 
underlying etiology. Traumatic brain injury may be an etiology for epilepsy, a consequence 
of epilepsy, or both, and one must seek historical data to determine whether the traumatic 
lesions predate the onset of epilepsy (eg, post-traumatic epilepsy) or whether the brain injury 
occurred during a seizure of unknown or other cause. Because late sequelae of traumatic 
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brain injury are a common etiology for epilepsy, not all SUDEP cases will have a natural 
manner of death.
4.5.8 Alcohol and drugs of abuse—The co-occurrence of epilepsy, acute symptomatic 
seizures, and substance abuse is common, with at least one-third of seizure-related deaths 
having a history of alcohol and/or street drug use.26,27 Among 83 deaths in persons with 
epilepsy/seizure history and no macroscopically obvious cause of death at autopsy, 21% of 
deaths were attributed to alcohol and or drugs.39 Death due to acute intoxication or 
withdrawal precludes classification as SUDEP, but should not prohibit inclusion of epilepsy 
as a contributor to death. Patients whose seizures occur exclusively in association with 
alcohol intoxication or withdrawal (provoked or acute symptomatic seizure) do not meet 
diagnostic criteria for epilepsy. However, alcohol use is a seizure trigger in people with 
epilepsy. Such seizures typically occur within 48 hours after peak blood levels, when the 
brain rebounds into a hyperexcitable state. Therefore, alcohol intoxication/withdrawal may 
contribute to the sudden death of a PWE, similar to other provocative factors such as missed 
medication or sleep deprivation. Complicating the dichotomy of epilepsy versus acute 
symptomatic seizures, alcohol abuse is an independent risk factor for epilepsy and may 
result from traumatic brain injury during intoxication, neurotoxic effects of alcohol, or 
kindling of epilepsy following repetitive bouts of alcohol withdrawal.40 Therefore, 
determining whether recurrent seizures in individuals with alcohol abuse are due to alcohol 
withdrawal or spontaneous, unprovoked seizures (epilepsy) can be very difficult. One study 
of first seizure in individuals with alcohol abuse found no consistent temporal relationship of 
seizure to last drink,41 suggesting that alcohol use and terminal seizure may be incidental in 
some decedents.
Cocaine42 or methamphetamine intoxication43 can trigger seizure activity in persons with or 
without epilepsy and is certified as an accidental drug death. However, if a person with 
documented epilepsy dies several hours after cocaine use and cocaine levels are low, then 
epilepsy may be a contributory cause of death. Many patients with epilepsy use cannabinoid 
oils and marijuana. The relevance of these substances to sudden death is unknown. However, 
synthetic cannabinoids (eg, spice, K2, bath salts) are pro-convulsant, and intoxication can 
cause seizures in individuals without epilepsy.44 Other drugs of abuse can provoke seizures, 
such as 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Molly), phencyclidine 
(PCP), and some opiates, typically in severe intoxication.45
4.5.9 Antiepileptic drugs (AEDs)—AEDs at effective doses may be associated with a 
reduced incidence of SUDEP.46 Subtherapeutic or absent AED levels are found in 57%–92% 
of SUDEP cases.27,30,35,47–49 However, finding subtherapeutic AED levels at autopsy has 
limited value in determining cause of death due to uncertainties in the correlation of 
postmortem whole blood levels to antemortem serum levels and the definition of a 
therapeutic level. Postmortem AED levels may not be comparable to antemortem levels. 
Among 16 institutionalized adults with epilepsy, paired antemortem and postmortem serum 
samples revealed that phenobarbital, phenytoin, and carbamazepine were significantly lower 
in postmortem than antemortem samples.50 An animal study found that phenytoin levels 
were higher antemortem, whereas carbamazepine levels were similar in antemortem and 
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postmortem samples.51 Postmortem alterations rather than patient noncompliance may 
explain the high incidence of subtherapeutic AED levels in SUDEP. Supporting this, there 
were no significant differences between postmortem AED levels between 44 SUDEP cases 
and 44 persons with epilepsy who died from non–epilepsy-related causes.52 The definition 
of a “therapeutic” range is limited because individual patients require different levels for 
efficacy. AED levels are informative postmortem when below detectable limits or in the 
lethal range.
Some AEDs can prolong the QT interval, but do not increase the risk of arrhythmia for most 
patients.53 When additional risk factors for arrhythmia are present, such as underlying 
cardiac dysfunction, electrolyte imbalance (eg, hypokalemia or hypomagnesemia), or 
concurrent use of other medications that prolong the QT interval, an additive effect from the 
AED may be considered, but it is not definitive. Fatal adverse drug reactions to AEDs (eg, 
hepatic failure, bone marrow suppression, Stevens-Johnson syndrome, disseminated 
intravascular coagulation, and pancreatitis) should be considered, but such deaths would not 
be classified as SUDEP. In the setting of very high, toxic levels of AEDs, suicide may be a 
consideration.
4.6 Questions 6: How are competing causes of sudden death assessed?
A PWE may have a medical history, or at postmortem examination may have natural disease 
findings, which can explain the sudden death. The most common is atherosclerotic 
cardiovascular disease54; others include cardiomegaly33 and myocarditis.55 Epilepsy is 
associated with such findings in some studies,20,56,57 and seizures can affect the 
cardiovascular system.58,59 Cardiac arrhythmia may be an undetectable cause of some 
SUDEPs.60 Although cardiovascular disease is the most frequent competing cause of death, 
the following recommendations apply to other findings associated with sudden death such as 
liver or pulmonary disease.
4.6.1 Coronary artery disease—Coronary atherosclerosis is highly prevalent in the 
developed world and is a common postmortem finding, which may or may not contribute to 
or cause sudden death in a PWE. In up to half of cases, sudden death is the initial 
manifestation of coronary artery disease.61 Characteristics of the plaque and vessel, degree 
of luminal stenosis, and location62,63 should be considered when weighing coronary disease 
as a competing cause of sudden death. These frequent pathological findings in a PWE may 
represent concurrent cardiac disease that is incidental to or explains the sudden death. Close 
examination of gross and microscopic findings, rather than just an estimate of the percent of 
coronary stenosis may facilitate deciphering these 2 competing causes of death. In a PWE, 
finding severe coronary stenosis, coronary thrombus, cardiomegaly, large ventricular 
chambers, and/or acute myocardial infarction or ischemia in territories served by stenotic 
coronary arteries may support cardiac disease rather than epilepsy as the cause of sudden 
death.
In a PWE with terminal seizure and postmortem acute coronary findings, the elevated stress 
and sympathetic response to the seizure may have triggered the acute coronary event. 
Seizures can also cause fatal arrhythmias14,60 or pulmonary dysfunction.64–66 Thus even 
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when a PWE has acute cardiac findings it is possible that a seizure triggered the cardiac 
ischemic event or arrhythmia, especially in the setting of preexisting cardiac disease, or vice 
versa. This scenario should be considered when there is evidence of seizure (eg, witnessed 
or tongue bite) and acute cardiac changes.
4.6.2 Structural cardiomyopathies and primary electrical causes of sudden 
cardiac death—Other cardiac causes of sudden death include structural cardiac diseases 
such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy, and valvular disease 
(eg, critical aortic stenosis); these causes are apparent on postmortem examination in a 
PWE. Nonstructural or “autopsy negative” molecular cardiac (primary electrical) diseases 
affecting cardiac channels and causing sudden arrhythmic death (eg, congenital long-QT or 
Brugada syndromes, catecholaminergic polymorphic ventricular tachycardia [CPVT]) are 
uncommon but potential causes of sudden death in a PWE. As with the general population, a 
cardiac etiology for sudden death cannot be entirely excluded with postmortem findings of a 
normal heart in a PWE.
4.6.3 Cardiac syncope mimicking seizure—Epilepsy is not the only cause for 
seizures. Some patients initially diagnosed with epilepsy are later found to have seizures due 
to a cardiovascular cause such as an arrhythmia.67,68 Rhythmic movements mistaken for 
generalized seizure can result from cerebral hypoperfusion during cardiac events such as 
ventricular tachycardia (VT), ventricular fibrillation (VF), idioventricular rhythms, or 
pulseless electrical activity.68 Detailed description of the duration (cardiac syncopal 
movements often <20 seconds; tonic–clonic seizures often >45 seconds) and type of 
movements witnessed (classic tonic phase [5–10 seconds] followed by clonic movements 
that progressively become less frequent over 30–180 seconds suggest a tonic–clonic seizure) 
may help determine seizure versus cardiac cause, but witness reports can be unreliable.
4.6.4 Supportive data: medical history, circumstances, and cardiac rhythms—
Data such as medical history, family history, witness account of terminal seizure event, and 
paramedic run-sheets with description of the fatal event and presenting rhythm, can help 
distinguish between epilepsy and a cardiac cause. A history of symptomatic cardiac disease 
or uncontrolled seizures while on multiple AEDs may support 1 diagnosis over another. 
Structural cardiomyopathies such as HCM and many primary electrical diseases have 
genetic causes, often with autosomal dominant inheritance patterns. Therefore, a family 
history of sudden cardiac death, particularly in persons younger than age 45 years, or sudden 
infant deaths, suggests the possibility of a genetic cause of sudden death in a PWE.
Circumstances and details surrounding the fatal seizure event can also be helpful. Sudden 
deaths due to cardiac primary electrical diseases (eg, long QT Syndrome [LQT1] or CPVT) 
occur during or just following peak exercise. Therefore, a report of seizure activity following 
collapse after vigorous exercise would favor a cardiac cause, whereas seizure activity at rest 
or in bed would favor epilepsy.
A rhythm recorded by paramedics during attempted resuscitation can also be helpful. The 
most common rhythms found during SUDEP are bradyarrhythmias,69 whereas VT or VF are 
commonly found in sudden cardiac death. Although VF is often considered the sine qua non 
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of cardiac/arrhythmic death, acute neurologic events can also cause neurocardiogenic VF70; 
therefore, VF at the time of fatal event does not exclude a neurologic cause.
4.7 Question 7: What are the optimal methods for determining and certifying cause of 
death, manner of death, and how injury occurred?
Death certificates are useful for families of the deceased, public health agencies, and 
researchers. Sections of the certificate relevant to this discussion include the following: 
Cause of Death (Part I), Other Significant Conditions Contributing to Death (Part II), 
Manner of Death, and, for unnatural deaths, the section labeled “Describe How Injury 
Occurred.” Recommendations for certifying deaths for several common vignettes in which 
epilepsy or a seizure-related event is thought to have contributed are provided in Table 3.
4.7.1 Cause of death—In sudden death among people with epilepsy for which no other 
cause of death is found, the sudden nature of death and its relationship to epilepsy should be 
emphasized on the death certificate. In such circumstances, there is no correct terminology 
that satisfies all. We suggest the following can be used interchangeably as the cause of 
death: “sudden death due to epilepsy,” “epilepsy,” or “sudden unexpected death in epilepsy.” 
When an individual with seizures that are not due to epilepsy dies under similar 
circumstances, listing “seizure disorder” as the cause of death is recommended. 
Acknowledging that clinical inconsistencies exist in the use of the terms epilepsy and 
seizure disorder, and that forensic case history terminology is variable, the medical examiner 
might substitute “seizure disorder” when a clinical diagnosis of epilepsy is not provided. In 
cases of sudden death due to epilepsy or seizure disorder in which the underlying etiology is 
known, the underlying etiology should be indicated (eg, epilepsy due to blunt head trauma or 
seizure disorder due to chronic alcoholism). In cases of death due to status epilepticus, 
epilepsy should also be mentioned if it is the underlying cause.
4.7.2 Other significant conditions—Part II of the death certificate should list factors 
contributing to death that did not result in the underlying cause of death indicated in Part I. 
Because the mechanism of death in epilepsy- or seizure-related deaths is considered a 
neurological event fatally disrupting cardiopulmonary function, coexisting cardiovascular or 
pulmonary disease (eg, moderate coronary artery disease or emphysema) could be 
interpreted as contributing factors. In decedents with a history of epilepsy or seizure disorder 
in which there is witnessed seizure activity at the time of death (or suggestive postmortem 
evidence) and cardiac or pulmonary pathology is considered insufficient to be a competing 
cause, deaths could still be certified as epilepsy, or one of the variations listed above, in Part 
I with the cardiac and/or pulmonary findings listed as contributing factors in Part II.
In more frequent scenarios involving unwitnessed deaths with a clear competing cause of 
death (eg, severe coronary artery atherosclerosis), it is recommended that both possible 
causes of death be indicated on the death certificate. An example would be an individual 
with epilepsy found dead in bed with 90% atherosclerotic narrowing of the left anterior 
descending coronary artery. One way to certify this death would be to put “atherosclerotic 
coronary artery disease” in Part I and “epilepsy” in Part II of the death certificate. Similarly, 
in an individual with epilepsy who is also found to have alcohol intoxication, both factors 
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should be listed on the death certificate. In such a circumstance, the placement of each 
diagnosis in either Part I or Part II will depend on the alcohol concentration.
4.7.3 Manner of death—A determination of seizure-related death does not preclude a 
nonnatural manner of death. When drowning cannot be excluded (eg, a decedent with 
epilepsy found dead, submerged in a bathtub), traditional practice is to attribute death to 
drowning and the manner as accident. However, addition of “epilepsy” or “seizure disorder” 
in Part II is encouraged when appropriate, since drowning of a PWE in a bathtub without 
drug intoxication would be extremely rare, making a seizure-related death likely. It is 
possible that deaths associated with epilepsy caused by prior injuries can be the result of an 
accident, homicide, or even suicide, and should be certified as such.71
4.7.4 How injury occurred—As this death certificate section will pertain to nonnatural 
deaths only, details regarding how an injury occurred should follow standard practices that 
often indicate the means and circumstances that led to the injury.
5 SUMMARY
The recommendations of this panel are based on the best evidence provided in the medical 
literature for the investigation, evaluation, and certification of epilepsy-related deaths at the 
time of review. The likely significant under-reporting of such deaths by medical examiners 
and coroners hampers advancements in research and public health, but more importantly 
fails to meet the responsibility of a medicolegal death investigation to provide accurate death 
certification. Use of these recommendations will improve the detection and reporting of 
epilepsy-related deaths.
The opinions and conclusions of this paper have been reviewed and approved by the NAME 
Board of Directors and as such are endorsed by the National Association of Medical 
Examiners. These opinions and positions are based on a consensus of the current literature, 
knowledge, and prevailing theories on this topic. As scientific knowledge and experience 
grow and change, the National Association of Medical Examiners reserves the right to revise 
or update these opinions.
The findings and conclusions in this study are those of the authors and do not necessarily 
represent the official position of the Centers for Disease Control and Prevention.
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APPENDIX. LITERATURE SEARCH STRATEGY
Databases: Medline, Medline In-Process & Other Non-Indexed Citations*, Embase
* Medline In-Process & Other Non-Indexed Citations not limited to humans
1. exp mortality/
2. exp epilepsy/
3. 1 and 2
4. epilep*.ti,ab.
5. seizure?.ti,ab.
6. 4 or 5
7. death?.ti,ab.
8. mortality.mp. or exp Mortality/
9. 7 or 8
10. 6 and 9
11. SUDEP.ti,ab.
12. exp Epilepsy/mo [Mortality]
13. “sudden death”.ti,ab.
14. exp Death, Sudden/
15. 13 or 14
16. 6 and 15
17. 3 or 10 or 11 or 12 or 16
18. exp toxicology/
19. toxicology.ti,ab.
20. exp histology/
21. histology.ti,ab.
22. exp Autopsy/
23. exp “Cause of Death”/
24. exp “Coroners and Medical Examiners”/
25. exp Jurisprudence/
26. exp Forensic Medicine/
27. Autopsy.ti,ab.
28. forensic pathology.ti,ab.
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29. Autopsies.ti,ab.
30. Autopsied.ti,ab.
31. Postmortem.ti,ab.
32. “Post mortem”.ti,ab.
33. “cause of death”.ti,ab.
34. Coroner?.ti,ab.
35. ((Medical or Forensic) adj Examiner?).ti,ab.
36. Jurisdiction.ti,ab.
37. Jurisprudence.ti,ab.
38. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 or 36 or 37
39. (scene adj3 (findings or investigation or examination or death)).ti,ab.
40. (death adj3 (classification or classify or investigate or investigation or certify or 
certification or determine or determination or cause)).ti,ab.
41. 38 or 39 or 40
42. 17 and 41
43. limit 42 to (English language and humans and yr=“1970 -Current”)
Database: PubMed.gov (excludes MEDLINE)
(((epilepsy[tiab] OR epileptic[tiab] OR epilepsia[tiab] OR seizure[tiab] OR seizures[tiab]) 
AND (death[tiab] OR deaths[tiab] OR mortality[tiab])) OR SUDEP[tiab] OR “Epilepsy/
mortality”[Mesh] OR ((“sudden death” [tiab] OR “death, sudden”[mesh]) AND 
epilepsy[tiab])) AND (“Autopsy”[Mesh] OR “Cause of Death”[Mesh] OR “Coroners and 
Medical Examiners”[Mesh] OR “Jurisprudence”[Mesh] OR “Forensic Medicine”[Mesh] OR 
Autopsy [tiab] OR Autopsies[tiab] OR Autopsied[tiab] OR Post-mortem[tiab] OR “Post 
mortem”[tiab] OR “cause of death”[tiab] OR Coroners[tiab] OR Coroner[tiab] OR “Medical 
Examiners” [tiab] OR “Medical Examiner”[tiab] OR “Jurisdiction” [tiab] OR 
“Jurisprudence” [tiab] OR “toxicology”[mesh] OR toxicology[tiab] OR “anatomy and 
histology” [Subheading] OR histology[tiab] OR (scene[-tiab] AND (findings[tiab] OR 
investigation[tiab] OR exam-ination[tiab] OR death[tiab])) OR (death[tiab] AND 
(classification[tiab] OR classify[tiab] OR investigate[tiab] OR investigation[tiab] OR 
certify[tiab] OR certification[-tiab] OR determine[tiab] OR determination[tiab] OR cause 
[tiab]))) NOT medline[sb] AND ((“1970/01/01”[PDAT]: “2016/12/31”[PDAT]) AND 
English[lang])
Legend: [mesh]=medical subject heading, [tiab]=term appears within title or abstract
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Years: 2011–2015
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Key Points
• Investigation of sudden unexpected deaths in people with epilepsy can be 
challenging, and autopsy can add essential information
• Death certificates likely underestimate the number of deaths in which 
epilepsy was a factor
• The National Association of Medical Examiners strives for consistent death 
investigation when people with epilepsy die suddenly
• Detailed seizure history from clinicians can greatly assist the accuracy of 
death certification by a medical examiner
Middleton et al. Page 20
Epilepsia. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Middleton et al. Page 21
TABLE 1
Questions formulated by the panel to address seizure-and epilepsy-related deaths
Question 1 Within the bounds of state law, which deaths require assumption of jurisdiction and performance of an autopsy?
Question 2 What constitutes appropriate and necessary scene investigation, epilepsy screening, and follow-up?
Question 3 When is it appropriate or necessary to perform toxicology and/or antiepileptic seizure medication testing?
Question 4 What are the best samples to collect for laboratory testing and histologic analysis?
Question 5 How are scene findings, autopsy findings, toxicology, and histology interpreted?
Question 6 How are competing causes of sudden death assessed?
Question 7 What are the optimal methods for determining and certifying cause of death, manner of death, and how injury occurred?
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TABLE 2
Recommended sections for microscopic analysis of the brain Striking the authors but leaving the reference 
citation number will match the format of how this paper is getting published in Academic Forensic Pathology.
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Hippocampus (right and left)
Amygdala (right and left)
Watershed (frontal and parietooccipital parasagittal regions)
Basal ganglia
Midbrain
Pons
Medulla (at area postrema)
Hypothalamus
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TABLE 3
Case vignettes with recommended death certificate wording
History Cause of death (Part I)
Other 
significant 
conditions (Part 
II) How injury occurred Manner
Decedent with epilepsy found dead 
in bed; no other COD discovered
Sudden death due to epilepsy N/A N
Decedent with epilepsy found dead 
in bed; competing cause of death 
such as severe coronary artery 
disease discovered
Atherosclerotic coronary artery 
disease
Epilepsy N/A N
Decedent with epilepsy found dead 
in bed; contributing factor such as 
moderate coronary artery disease 
discovered
Sudden death due to epilepsy Atherosclerotic 
coronary artery 
disease
N/A N
Decedent with epilepsy found dead 
in bed; ethanol concentration 
reported as 0.41 g/dL
Acute ethanol intoxication Epilepsy Decedent with epilepsy 
ingested an excess of ethanol
A
Decedent with epilepsy due to blunt 
head trauma occurring from an 
accidental fall 10 y prior
Epilepsy due to blunt head trauma 
due to fall
Decedent with epilepsy found 
dead; suffered head injury in 
fall 10 y prior
A
Decedent with epilepsy due to blunt 
head trauma occurring from an 
assault 10 y prior
Epilepsy due to blunt head trauma 
due to assault
Decedent with epilepsy found 
dead; suffered head injury in 
assault 10 y prior
H
Decedent with epilepsy found dead, 
submerged in bathtub; no other COD 
discovered
Drowning Epilepsy Decedent with epilepsy found 
submerged in bathtub
A
Driver with epilepsy had witnessed 
seizure in motor vehicle accident; 
examination revealed no competing 
COD
Sudden death due to epilepsy N/A N
N, natural; A, accident; H, homicide; N/A, not applicable.
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